313 related articles for article (PubMed ID: 12208752)
21. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Small GW; Shi YY; Edmund NA; Somasundaram S; Moore DT; Orlowski RZ
Mol Pharmacol; 2004 Dec; 66(6):1478-90. PubMed ID: 15448190
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
Hamner JB; Dickson PV; Sims TL; Zhou J; Spence Y; Ng CY; Davidoff AM
Surgery; 2007 Aug; 142(2):185-91. PubMed ID: 17689684
[TBL] [Abstract][Full Text] [Related]
24. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
[TBL] [Abstract][Full Text] [Related]
25. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
26. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
30. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
Zou W; Yue P; Lin N; He M; Zhou Z; Lonial S; Khuri FR; Wang B; Sun SY
Clin Cancer Res; 2006 Jan; 12(1):273-80. PubMed ID: 16397052
[TBL] [Abstract][Full Text] [Related]
31. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
33. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
[TBL] [Abstract][Full Text] [Related]
34. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L
Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942
[TBL] [Abstract][Full Text] [Related]
37. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
38. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913
[TBL] [Abstract][Full Text] [Related]
39. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
40. Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.
Jia H; Ge F; Lu X; Zeng H; Li L; Chen Z; Lu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):784-91. PubMed ID: 20818069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
